These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 38296052

  • 1. CDKN2A-p16 Deletion and Activated KRASG12D Drive Barrett's-Like Gland Hyperplasia-Metaplasia and Synergize in the Development of Dysplasia Precancer Lesions.
    Sun J, Sepulveda JL, Komissarova EV, Hills C, Seckar TD, LeFevre NM, Simonyan H, Young C, Su G, Del Portillo A, Wang TC, Sepulveda AR.
    Cell Mol Gastroenterol Hepatol; 2024; 17(5):769-784. PubMed ID: 38296052
    [Abstract] [Full Text] [Related]

  • 2. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
    Kunze B, Wein F, Fang HY, Anand A, Baumeister T, Strangmann J, Gerland S, Ingermann J, Münch NS, Wiethaler M, Sahm V, Hidalgo-Sastre A, Lange S, Lightdale CJ, Bokhari A, Falk GW, Friedman RA, Ginsberg GG, Iyer PG, Jin Z, Nakagawa H, Shawber CJ, Nguyen T, Raab WJ, Dalerba P, Rustgi AK, Sepulveda AR, Wang KK, Schmid RM, Wang TC, Abrams JA, Quante M.
    Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
    [Abstract] [Full Text] [Related]

  • 3. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
    Brankley SM, Fritcher EG, Smyrk TC, Keeney ME, Campion MB, Voss JS, Clayton AC, Wang KK, Lutzke LS, Kipp BR, Halling KC.
    Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J.
    Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
    [Abstract] [Full Text] [Related]

  • 7. The diagnosis and management of Barrett's esophagus.
    DeMeester SR, DeMeester TR.
    Adv Surg; 1999 Apr; 33():29-68. PubMed ID: 10572561
    [Abstract] [Full Text] [Related]

  • 8. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.
    Moyes LH, McEwan H, Radulescu S, Pawlikowski J, Lamm CG, Nixon C, Sansom OJ, Going JJ, Fullarton GM, Adams PD.
    J Pathol; 2012 Sep; 228(1):99-112. PubMed ID: 22653845
    [Abstract] [Full Text] [Related]

  • 9. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus].
    Osminin SV, Vetshev FP, Rudenko VV, Zaletaev DV, Khorobrykh TV, Nemtsova MV.
    Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323
    [Abstract] [Full Text] [Related]

  • 10. Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma.
    Beilstein M, Silberg D.
    Gastroenterol Clin North Am; 2002 Jun; 31(2):461-79, ix. PubMed ID: 12134613
    [Abstract] [Full Text] [Related]

  • 11. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJ, Krishnadath KK.
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [Abstract] [Full Text] [Related]

  • 12. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ, Falk GW.
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Transcriptionally active human papillomavirus is strongly associated with Barrett's dysplasia and esophageal adenocarcinoma.
    Rajendra S, Wang B, Snow ET, Sharma P, Pavey D, Merrett N, Ball MJ, Brain T, Fernando R, Robertson IK.
    Am J Gastroenterol; 2013 Jul; 108(7):1082-93. PubMed ID: 23588239
    [Abstract] [Full Text] [Related]

  • 16. Quantitative analysis of p16 methylation in Barrett's carcinogenesis.
    Chueca E, Valero A, Hördnler C, Puertas A, Carrera P, García-González MA, Strunk M, Lanas A, Piazuelo E.
    Ann Diagn Pathol; 2020 Aug; 47():151554. PubMed ID: 32570024
    [Abstract] [Full Text] [Related]

  • 17. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A, Bahjri K, Jackson C, Griffin R.
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [Abstract] [Full Text] [Related]

  • 18. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E.
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [Abstract] [Full Text] [Related]

  • 19. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D, Fléjou JF.
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [Abstract] [Full Text] [Related]

  • 20. Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett's esophagus: a matched case-control study.
    Helminen O, Melkko J, Saarnio J, Sihvo E, Kuopio T, Ohtonen P, Kauppila JH, Karttunen TJ, Huhta H.
    Virchows Arch; 2022 Sep; 481(3):467-476. PubMed ID: 35614270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.